Merck KGaA said that cohort A met the primary endpoint in the Phase II lupus trial but cohort B failed to meet its primary ...

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis ...

A new study identifies eight domains of active systemic #lupus erythematosus for defining meaningful treatment response in ...

In this randomized trial, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a ...

The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

Investigators assessed the frequency of lupus flares in patients with kidney failure undergoing dialysis or with a kidney transplant.

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

Riya began to get "off" feelings at the age of 22. Her symptoms were subtle: body aches, periodic low-grade fevers, fatigue ...

The following is a summary of “2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and ...

Antibodies targeting the TFAM protein could increase the risk of blood clotting complications in people with lupus, a study ...

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded ...

General and administrative (G&A) expenses were $12.4 million for the first quarter of 2025, which included $5.1 million of restructuring expenses in March 2025. Non-cash stock-based compensation ...